KIT and acute myeloid leukemia: pDCs in pDC-AML are characterized by a full spectrum of maturation composed of various stages of pDCs, including early forms expressing CD34 and CD117 with low levels of CD4 and CD303, intermediate forms, and late/mature forms that are completely negative for CD34 and CD117 expression with the high expression of CD4 and CD303 [17,18].